• About us
• Contact

Advertisement

Organisation › Details

Amolyt Pharma SAS

Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. *

 

	Start	2020-06-02 renamed
	Group	AstraZeneca (Group)
	Predecessor	Alizé Pharma III SAS (Alizé Pharma 3)
	Industry	peptide-based drug
	Person	Abribat, Thierry (Alizé Pharma 2007– President + Founder)
	Region	Lyon
	Country	France
	Street	15 chemin du Saquin Espace Européen
	City	69130 Ecully
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA.
		Record changed: 2024-03-30

Advertisement

More documents for AstraZeneca (Group)

• [1] Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA....
• [2] Bico Group AB. (8/21/23). "Press Release: Maria Forss Is Appointed New President and CEO of Bico Group AB (publ)"....
• [3] SandboxAQ. (6/22/23). "Press Release: SandboxAQ Announces Biopharma Molecular Simulation Division to Speed Life-Saving Drugs to Patients Through AI and Quantum Solutions". Palo Alto, CA....
• [4] Transgene S.A.. (5/5/23). "Press Release: Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio". Strasbourg....
• [5] AstraZeneca plc. (1/9/23). "Press Release: AstraZeneca to Acquire CinCor Pharma to Strengthen Cardiorenal Pipeline"....
• [6] Amolyt Pharma SAS. (1/6/23). "Press Release: Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group". Lyon & Cambridge, MA....
• [7] RQ Biotechnology Ltd.. (5/17/22). "Press Release: RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies". London....
• [8] Amolyt Pharma SAS. (2/4/22). "Press Release: Amolyt Pharma Selected for the French Tech 120 Program". Lyon & Cambridge, MA....
• [9] CinCor Pharma, Inc.. (10/12/21). "Press Release: CinCor Pharma Raises $143 Million in Series B Financing". Cincinnati, OH....
• [10] Amolyt Pharma SAS. (9/16/21). "Press Release: Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners". Lyon & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.